Jyong Biotech Ltd. MENS
1.74 USD -0.04 (-2.25%)
At closeNov 5, 2026, 4:32 AM EST
1.61 -0.13 -7.47%
Pre-market · Nov 5, 4:32 AM ET
1.66 Day range 1.85
1.43 52-week range 43.78
- YTD
- -55.95%
- 1 year
- -95.75%
- Market cap
- 132.29M
- EPS (ttm)
- -0.06
- Shares out
- 76.03M
- YTD return
- -55.95%
- 1-year return
- -95.75%
- Volume
- 83.14K
- Avg volume
- 41.88K
- Open
- 1.70
- Previous close
- 1.78
- Day's range
- 1.66 – 1.85
- 52-week range
- 1.43 – 43.78
1D +0.06 (+3.37%)
Key statistics
- Enterprise value
- 1.16B
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -1.73M
- Total cash
- 98.00K
- Total debt
- 18.14M
- Return on equity
- 0.00%
- Short % of float
- 0.45%
- 50-day average
- 40.49
- 200-day average
- 36.26
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
MENS Revenue — quarterly 47.68M
MENS Net income — quarterly 2.69M
MENS EPS — quarterly 0.26
About Jyong Biotech Ltd.
Jyong Biotech Ltd., a science-driven biotechnology company, develops and commercializes plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops MCS-2 for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder pain syndrome. The company was founded in 2002 and is headquartered in New Taipei City, Taiwan.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Taiwan
- Website
- jyongbio.com
News
Your note
Sign in to keep a note on MENS — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Geode Capital Management, LLC | 0.07% | 53,844 | 157.22K | Sep 29, 2025 |
| HRT Financial LP | 0.03% | 20,819 | 60.79K | Sep 29, 2025 |
| Millennium Management Llc | 0.02% | 13,013 | 38.00K | Sep 29, 2025 |
| Citadel Advisors Llc | 0.02% | 12,641 | 36.91K | Sep 29, 2025 |
| BNP Paribas Financial Markets | 0.00% | 1,698 | 4.96K | Sep 29, 2025 |
| UBS Group AG | 0.00% | 537 | 1.57K | Sep 29, 2025 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund | 0.05% | 35,802 | 104.54K | Sep 29, 2025 |
| Fidelity Commonwealth Trust-Fidelity Nasdaq Composite Index ETF | 0.02% | 18,042 | 52.68K | Sep 29, 2025 |